neuroendocrine tumours (pNET/epNET)
Oncology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cabozantinib Treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumour (pNET) or extra-pancreatic neuroendocrine… | Jul 2025 | Recommended with restriction | 2 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group |
Who spoke
Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group
What the PBS pays
$56M in government benefit over 2024–25, across 5,867 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cabozantinib | $55.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.